Back to
Dr Heloisa Zaccaron Milioli

Dr Heloisa Zaccaron Milioli

Conjoint Lecturer
Medicine & Health
School of Clinical Medicine

Dr Heloisa Milioli is a Senior Research Officer in Christine Chaffer’s Laboratory at the Garvan Institute of Medical Research. She integrates molecular biology and computational approaches to investigate the complex mechanisms driving breast cancer development, progression and metastasis. Her research focuses on non-genetic mechanisms governing cell state plasticity and therapy resistance. Her work has been supported by Cancer Institute NSW (2018–2020, Early Career Fellowship), Cancer Council NSW (2023–2026), Tour de Cure (2024) and others. Her research on the context-dependent role of the androgen receptor (AR) in both primary and resistant breast cancer—published in Nature Medicine, Nature Structural & Molecular Biology and MedRxiv—has helped shape ongoing clinical trials (NCT02463032, NCT04947189), underscoring her commitment to improving outcomes for cancer patients in Australia and worldwide.

* Eligible to supervise Honours, Master and PhD students.
Phone
0422262707
E-mail
h.milioli@garvan.org.au
Location
Garvan Institute of Medical Research 384 Victoria Street, Darlinghurst NSW 2010, Australia.
  • Journal articles | 2025
    Alexandrou S; Lee CS; Fernandez KJ; Wiharja CE; Eshraghi L; Reeves J; Reed DA; Portman N; Phan Z; Milioli HH; Nikolic I; Cadell AL; Croucher DR; Simpson KJ; Lim E; Hickey TE; Millar EKA; Alves CL; Ditzel HJ; Caldon CE, 2025, 'JNK pathway suppression mediates insensitivity to combination endocrine therapy and CDK4/6 inhibition in ER+ breast cancer', Journal of Experimental and Clinical Cancer Research, 44, http://dx.doi.org/10.1186/s13046-025-03466-9
    Journal articles | 2025
    Chaffer CL; Milioli HH; San Juan BP; Dear RF; Liu JJ, 2025, 'Abstract 4744: State-gating cancer to prevent chemotherapy-resistance', Cancer Research, 85, pp. 4744 - 4744, http://dx.doi.org/10.1158/1538-7445.am2025-4744
    Journal articles | 2024
    Achinger-Kawecka J; Stirzaker C; Portman N; Campbell E; Chia KM; Du Q; Laven-Law G; Nair SS; Yong A; Wilkinson A; Clifton S; Milioli HH; Alexandrou S; Caldon CE; Song J; Khoury A; Meyer B; Chen W; Pidsley R; Qu W; Gee JMW; Schmitt A; Wong ES; Hickey TE; Lim E; Clark SJ, 2024, 'The potential of epigenetic therapy to target the 3D epigenome in endocrine-resistant breast cancer', Nature Structural and Molecular Biology, 31, pp. 498 - 512, http://dx.doi.org/10.1038/s41594-023-01181-7
    Journal articles | 2024
    Gemma C; Lai CF; Singh AK; Belfiore A; Portman N; Milioli HZ; Periyasamy M; Raafat S; Nicholls AJ; Davies CM; Patel NR; Simmons GM; Fan H; Nguyen VTM; Magnani L; Rakha E; Martin LA; Lim E; Charles Coombes R; Pruneri G; Buluwela L; Ali S, 2024, 'Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor–Targeted Therapy Drives Resistance in Breast Cancer', Cancer Research, 84, pp. 4283 - 4297, http://dx.doi.org/10.1158/0008-5472.CAN-24-0013
    Journal articles | 2024
    Sahoo S; Ramu S; Nair MG; Pillai M; San Juan BP; Milioli HZ; Mandal S; Naidu CM; Mavatkar AD; Subramaniam H; Neogi AG; Chaffer CL; Prabhu JS; Somarelli JA; Jolly MK, 2024, 'Increased prevalence of hybrid epithelial/mesenchymal state and enhanced phenotypic heterogeneity in basal breast cancer', Iscience, 27, http://dx.doi.org/10.1016/j.isci.2024.110116
    Journal articles | 2023
    McKinnon JC; Milioli HH; Purcell CA; Chaffer CL; Wadie B; Alexandrov T; Mitchell TW; Ellis SR, 2023, 'Enhancing metabolite coverage in MALDI-MSI using laser post-ionisation (MALDI-2)', Analytical Methods, 15, pp. 4311 - 4320, http://dx.doi.org/10.1039/d3ay01046e
    Journal articles | 2023
    Shehadeh-Tout F; Milioli HH; Roslan S; Jansson PJ; Dharmasivam M; Graham D; Anderson R; Wijesinghe T; Azad MG; Richardson DR; Kovacevic Z, 2023, 'Innovative thiosemicarbazones that induce multi-modal mechanisms to down-regulate estrogen-, progesterone-, androgen- and prolactin-receptors in breast cancer', Pharmacological Research, 193, pp. 106806, http://dx.doi.org/10.1016/j.phrs.2023.106806
    Journal articles | 2021
    Hickey TE; Selth LA; Chia KM; Laven-Law G; Milioli HH; Roden D; Jindal S; Hui M; Finlay-Schultz J; Ebrahimie E; Birrell SN; Stelloo S; Iggo R; Alexandrou S; Caldon CE; Abdel-Fatah TM; Ellis IO; Zwart W; Palmieri C; Sartorius CA; Swarbrick A; Lim E; Carroll JS; Tilley WD, 2021, 'The androgen receptor is a tumor suppressor in estrogen receptor–positive breast cancer', Nature Medicine, 27, pp. 310 - 320, http://dx.doi.org/10.1038/s41591-020-01168-7
    Journal articles | 2020
    Heng B; Bilgin AA; Lovejoy DB; Tan VX; Milioli HH; Gluch L; Bustamante S; Sabaretnam T; Moscato P; Lim CK; Guillemin GJ, 2020, 'Differential kynurenine pathway metabolism in highly metastatic aggressive breast cancer subtypes: beyond IDO1-induced immunosuppression', Breast Cancer Research, 22, http://dx.doi.org/10.1186/s13058-020-01351-1
    Journal articles | 2020
    Milioli HH; Alexandrou S; Lim E; Caldon CE, 2020, 'Cyclin E1 and cyclin E2 in ER+ breast cancer: Prospects as biomarkers and therapeutic targets', Endocrine Related Cancer, 27, pp. R93 - R112, http://dx.doi.org/10.1530/ERC-19-0501
    Journal articles | 2020
    Portman N; Milioli HH; Alexandrou S; Coulson R; Yong A; Fernandez KJ; Chia KM; Halilovic E; Segara D; Parker A; Haupt S; Haupt Y; Tilley WD; Swarbrick A; Caldon CE; Lim E, 2020, 'MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer', Breast Cancer Research, 22, pp. 87, http://dx.doi.org/10.1186/s13058-020-01318-2
    Journal articles | 2019
    Chia KM; Milioli H; Portman N; Laven-Law G; Coulson R; Yong A; Segara D; Parker A; Caldon CE; Deng N; Swarbrick A; Tilley WD; Hickey TE; Lim E, 2019, 'Non-canonical AR activity facilitates endocrine resistance in breast cancer', Endocrine Related Cancer, 26, pp. 251 - 264, http://dx.doi.org/10.1530/ERC-18-0333
    Journal articles | 2017
    Milioli HH; Tishchenko I; Riveros C; Berretta R; Moscato P, 2017, 'Basal-like breast cancer: molecular profiles, clinical features and survival outcomes', BMC Medical Genomics, 10, http://dx.doi.org/10.1186/s12920-017-0250-9
    Journal articles | 2016
    Milioli HH; Vimieiro R; Tishchenko I; Riveros C; Berretta R; Moscato P, 2016, 'Iteratively refining breast cancer intrinsic subtypes in the METABRIC dataset', Biodata Mining, 9, http://dx.doi.org/10.1186/s13040-015-0078-9
    Journal articles | 2016
    Milioli HH, 2016, 'Life as an early career researcher: Interview with Heloisa Helena Milioli', Future Science Oa, 2, http://dx.doi.org/10.4155/fsoa-2016-0033
    Journal articles | 2016
    Oliveira NCS; Gomig THB; Milioli HH; Cordeiro F; Costa GG; Urban CA; Lima RS; Cavalli IJ; Ribeiro EMSF, 2016, 'Comparative proteomic analysis of ductal and lobular invasive breast carcinoma', Genetics and Molecular Research, 15, http://dx.doi.org/10.4238/gmr.15027701
    Journal articles | 2016
    Tishchenko I; Milioli HH; Riveros C; Moscato P, 2016, 'Extensive transcriptomic and genomic analysis provides new insights about luminal breast cancers', Plos One, 11, http://dx.doi.org/10.1371/journal.pone.0158259
    Journal articles | 2015
    Milioli HH; Sousa KS; Kaviski R; Oliveira NCDS; De Andrade Urban C; De Lima RS; Cavalli IJ; De Souza Fonseca Ribeiro EM, 2015, 'Comparative proteomics of primary breast carcinomas and lymph node metastases outlining markers of tumor invasion', Cancer Genomics and Proteomics, 12, pp. 89 - 101
    Journal articles | 2015
    Milioli HH; Tishchenko I; Riveros C; Berretta R; Moscato P, 2015, 'Molecular classification of basal-like breast cancer subtypes based on predictive survival markers', Annals of Oncology, 26, pp. iii15, http://dx.doi.org/10.1093/annonc/mdv117.11
    Journal articles | 2015
    Milioli HH; Tishchenko I; Riveros C; Sakoff J; Berretta R; Moscato P, 2015, 'Consensus on breast cancer cell lines classification for an effective and efficient clinical decision-making', Annals of Oncology, 26, pp. iii31, http://dx.doi.org/10.1093/annonc/mdv121.08
    Journal articles | 2015
    Milioli HH; Vimieiro R; Riveros C; Tishchenko I; Berretta R; Moscato P, 2015, 'The discovery of novel biomarkers improves breast cancer intrinsic subtype prediction and reconciles the labels in the METABRIC data set', Plos One, 10, http://dx.doi.org/10.1371/journal.pone.0129711
  • Preprints | 2025
    Alexandrou S; Lee CS; Fernandez KJ; Wiharja CE; Eshraghi L; Reeves J; Reed DA; Portman N; Phan Z; Milioli HH; Nikolic I; Cadell AL; Croucher DR; Simpson KJ; Lim E; Hickey TE; Millar EKA; Alves CL; Ditzel HJ; Caldon CE, 2025, JNK pathway suppression drives resistance to combination endocrine therapy and CDK4/6 inhibition in ER+ breast cancer, http://dx.doi.org/10.1101/2025.01.08.631992
    Other | 2024
    Gemma C; Lai C-F; Singh AK; Belfiore A; Portman N; Milioli HZ; Periyasamy M; Raafat S; Nicholls AJ; Davies CM; Patel NR; Simmons GM; Fan H; Nguyen VTM; Magnani L; Rakha E; Martin L-A; Lim E; Coombes RC; Pruneri G; Buluwela L; Ali S, 2024, Data from Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor–Targeted Therapy Drives Resistance in Breast Cancer, http://dx.doi.org/10.1158/0008-5472.c.7585327
    Other | 2024
    Gemma C; Lai C-F; Singh AK; Belfiore A; Portman N; Milioli HZ; Periyasamy M; Raafat S; Nicholls AJ; Davies CM; Patel NR; Simmons GM; Fan H; Nguyen VTM; Magnani L; Rakha E; Martin L-A; Lim E; Coombes RC; Pruneri G; Buluwela L; Ali S, 2024, Supplementary Figures from Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor–Targeted Therapy Drives Resistance in Breast Cancer, http://dx.doi.org/10.1158/0008-5472.28032298
    Other | 2024
    Gemma C; Lai C-F; Singh AK; Belfiore A; Portman N; Milioli HZ; Periyasamy M; Raafat S; Nicholls AJ; Davies CM; Patel NR; Simmons GM; Fan H; Nguyen VTM; Magnani L; Rakha E; Martin L-A; Lim E; Coombes RC; Pruneri G; Buluwela L; Ali S, 2024, Supplementary Table 3 from Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor–Targeted Therapy Drives Resistance in Breast Cancer, http://dx.doi.org/10.1158/0008-5472.28032295
    Other | 2024
    Gemma C; Lai C-F; Singh AK; Belfiore A; Portman N; Milioli HZ; Periyasamy M; Raafat S; Nicholls AJ; Davies CM; Patel NR; Simmons GM; Fan H; Nguyen VTM; Magnani L; Rakha E; Martin L-A; Lim E; Coombes RC; Pruneri G; Buluwela L; Ali S, 2024, Supplementary Table 4 from Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor–Targeted Therapy Drives Resistance in Breast Cancer, http://dx.doi.org/10.1158/0008-5472.28032292
    Other | 2024
    Gemma C; Lai C-F; Singh AK; Belfiore A; Portman N; Milioli HZ; Periyasamy M; Raafat S; Nicholls AJ; Davies CM; Patel NR; Simmons GM; Fan H; Nguyen VTM; Magnani L; Rakha E; Martin L-A; Lim E; Coombes RC; Pruneri G; Buluwela L; Ali S, 2024, Supplementary Table 5 from Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor–Targeted Therapy Drives Resistance in Breast Cancer, http://dx.doi.org/10.1158/0008-5472.28032289
    Other | 2024
    Gemma C; Lai C-F; Singh AK; Belfiore A; Portman N; Milioli HZ; Periyasamy M; Raafat S; Nicholls AJ; Davies CM; Patel NR; Simmons GM; Fan H; Nguyen VTM; Magnani L; Rakha E; Martin L-A; Lim E; Coombes RC; Pruneri G; Buluwela L; Ali S, 2024, Supplementary Table 6 from Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor–Targeted Therapy Drives Resistance in Breast Cancer, http://dx.doi.org/10.1158/0008-5472.28032286
    Other | 2024
    Gemma C; Lai C-F; Singh AK; Belfiore A; Portman N; Milioli HZ; Periyasamy M; Raafat S; Nicholls AJ; Davies CM; Patel NR; Simmons GM; Fan H; Nguyen VTM; Magnani L; Rakha E; Martin L-A; Lim E; Coombes RC; Pruneri G; Buluwela L; Ali S, 2024, Supplementary Table S1 from Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor–Targeted Therapy Drives Resistance in Breast Cancer, http://dx.doi.org/10.1158/0008-5472.28032283
    Other | 2024
    Gemma C; Lai C-F; Singh AK; Belfiore A; Portman N; Milioli HZ; Periyasamy M; Raafat S; Nicholls AJ; Davies CM; Patel NR; Simmons GM; Fan H; Nguyen VTM; Magnani L; Rakha E; Martin L-A; Lim E; Coombes RC; Pruneri G; Buluwela L; Ali S, 2024, Supplementary Table S2 from Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor–Targeted Therapy Drives Resistance in Breast Cancer, http://dx.doi.org/10.1158/0008-5472.28032280
    Preprints | 2023
    Mckinnon J; Milioli H; Purcell C; Chaffer C; Wadie B; Alexandrov T; Mitchell T; Ellis S, 2023, Enhancing Metabolite Coverage in MALDI-MSI using Laser Post-Ionisation (MALDI-2)., http://dx.doi.org/10.26434/chemrxiv-2023-sptss
    Preprints | 2023
    Shehadeh-Tout F; Milioli H; Roslan S; Jansson P; Dharmasivam M; Graham D; Anderson R; Wijesinghe T; Azad MG; Richardson D; Kovacevic Z, 2023, An Innovative Non-Hormonal Strategy Targeting Redox Active Metals to Down-Regulate Estrogen-, Progesterone-, Androgen- and Prolactin-Receptors in Breast Cancer, http://dx.doi.org/10.1101/2023.02.02.526543
    Conference Abstracts | 2022
    Juan BPS; Hediyah-Zadeh S; Rangel L; Rodriguez V; Milioli HH; Kohane F; Purcell CA; Hickey TE; Goldstein LD; Lock JG; Davis MJ; Chaffer CL, 2022, 'Abstract 1029: The anti-androgen seviteronel sensitizes triple-negative breast cancer to chemotherapy', in Cancer Research, American Association for Cancer Research (AACR), Vol. 82, pp. 1029 - 1029, http://dx.doi.org/10.1158/1538-7445.am2022-1029
    Conference Papers | 2022
    Juan BPS; Hediyah-Zadeh S; Rangel L; Rodriguez V; Milioli HH; Kohane F; Purcell CA; Hickey TE; Goldstein LD; Lock JG; Davis MJ; Chaffer CL, 2022, 'The anti-androgen seviteronel sensitizes triple-negative breast cancer to chemotherapy', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, LA, New Orleans, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), LA, New Orleans, 08 April 2022 - 13 April 2022, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000892509505326&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Preprints | 2022
    San Juan B; Hediyeh-Zadeh S; Rangel L; Milioli H; Rodriguez V; Bunkum A; Kohane F; Purcell C; Bhuva D; Kurumlian A; Castillo L; Lim E; Gill A; Ganju V; Dear R; O’Toole S; Vargas C; Hickey T; Goldstein L; Lock J; Davis M; Chaffer C, 2022, Targeting phenotypic plasticity prevents metastasis and the development of chemotherapy-resistant disease, http://dx.doi.org/10.1101/2022.03.21.22269988
    Preprints | 2021
    Achinger-Kawecka J; Stirzaker C; Portman N; Campbell E; Chia K-M; Du Q; Laven-Law G; Nair S; Yong A; Wilkinson A; Clifton S; Milioli H; Alexandrou S; Caldon E; Song J; Khoury A; Meyer B; Gee JMW; Schmitt A; Wong E; Hickey T; Lim E; Clark S, 2021, Epigenetic therapy targets the 3D epigenome in endocrine-resistant breast cancer, http://dx.doi.org/10.1101/2021.06.21.449340
    Conference Abstracts | 2021
    Heng B; Bilgin A; Tan V; Milioli H; Lovejoy D; Bustamante S; Gluch L; Moscato P; Lim C; Guillemin G, 2021, 'Aggressive breast cancer subtype eats tryptophan!', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 17, pp. 15 - 16, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000693805000020&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2021
    Portman N; Milioli H; Alexandrou S; Coulson R; Yong A; Fernandez K; Chia K; Halilovic E; Segara D; Parker A; Haupt S; Haupt Y; Tilley W; Swarbrick A; Caldon L; Lim E, 2021, 'Abstract PS18-17: Mdm2 inhibition synergises with endocrine therapy or cdk4/6 inhibition for the treatment of estrogen receptor-positive breast cancer', in Cancer Research, American Association for Cancer Research (AACR), http://dx.doi.org/10.1158/1538-7445.sabcs20-ps18-17
    Preprints | 2020
    Heng B; Bilgin AA; Lovejoy DB; Tan VX; Milioli HH; Gluch L; Busamante S; Sabaretnam T; Moscato P; Lim CK; Guillemin GJ, 2020, Differential kynurenine pathway metabolism in highly-metastatic aggressive breast cancer subtypes: beyond IDO1-induced immunosuppression, http://dx.doi.org/10.21203/rs.3.rs-57673/v2
    Preprints | 2020
    Heng B; Bilgin AA; Lovejoy DB; Tan VX; Milioli HH; Gluch L; Moscato P; Lim CK; Guillemin GJ, 2020, Differential kynurenine pathway metabolism in highly-metastatic aggressive breast cancer subtypes: beyond IDO1-induced immunosuppression, http://dx.doi.org/10.21203/rs.3.rs-57673/v1
    Conference Abstracts | 2020
    Hickey T; Selth L; Chia KM; Milioli HH; Laven-Law G; Roden D; Jindal S; Hui M; Ebrahimie E; Birrel SN; Stello S; Iggo R; Alexandrou S; Caldon L; Finlay-Shultz J; Abdel-Fatah TM; Ellis IO; Zwart W; Palmieri C; Sartorious CA; Swarbrick A; Lim E; Carrol JS; Tilley WD, 2020, 'The androgen receptor is a tumour suppressor in estrogen receptor positive breast cancer', in Journal of the Endocrine Society, Oxford University Press (OUP), Vol. 4, pp. or05 - or06, presented at Endocrine Society Annual Meeting, http://dx.doi.org/10.1210/jendso/bvaa046.982
    Conference Papers | 2020
    Lim E; Milioli HH; Alexandrou S; Coulson R; Yong A; Fernandez KJ; Chia K; Halilovic E; Segara D; Parker A; Haupt S; Haupt Y; Tilley WD; Swarbrick A; Caldon EC; Portman N, 2020, 'MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 110 - 110
    Conference Abstracts | 2020
    Portman N; Milioli H; Alexandrou S; Coulson R; Yong A; Fernandez K; Chia K; Halilovic E; Segara D; Parker A; Haupt S; Haupt Y; Tilley W; Swarbrick A; Caldon L; Lim E, 2020, 'Mdm2 inhibition synergises with endocrine therapy or cdk4/6 inhibition for the treatment of estrogen receptor-positive breast cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, ELECTR NETWORK, Vol. 81, presented at San Antonio Breast Cancer Virtual Symposium, ELECTR NETWORK, 08 December 2020 - 11 December 2020
    Preprints | 2020
    Portman N; Milioli H; Alexandrou S; Coulson R; Yong A; Fernandez K; Chia KM; Segara D; Parker A; Haupt S; Haupt Y; Tilley W; Swarbrick A; Caldon E; Lim E, 2020, MDM2 Inhibition in Combination with Endocrine Therapy and CDK4/6 Inhibition for the Treatment of ER-Positive Breast Cancer, http://dx.doi.org/10.1101/2020.06.09.140921
    Preprints | 2020
    Tilley W; Hickey T; Selth L; Chia KM; Milioli H; Laven-Law G; Roden D; Jindal S; Hui M; Finlay-Schultz J; Ebrahimie E; Birrell S; Stelloo S; Iggo R; Alexandrou S; Caldon C; Abdel-Fatah T; Ellis I; Zwart W; Palmieri C; Sartorius C; Swarbrick A; Lim E; Carroll J, 2020, The Androgen Receptor is a Tumour Suppressor in Estrogen Receptor Positive Breast Cancer, http://dx.doi.org/10.21203/rs.3.rs-62718/v1
    Conference Abstracts | 2019
    Alexandrou S; Milioli HH; Portman N; Lee C; Fernandez K; Blake D; Lim E; Caldon L, 2019, 'S phase dysregulation occurs following resistance to CDK4/6 inhibition ER+ breast cancer', in Oncolabs, Bioscientifica, presented at 7th PacRim Breast & Prostate Cancer Meeting, http://dx.doi.org/10.1530/oncolabs.1.P001
    Conference Abstracts | 2019
    Chia KM; Milioli HH; Portman N; Laven-Law G; Coulson R; Young A; Segara D; Parker A; Caldon L; Deng N; Swarbrick A; Tilley W; Hickey T; Lim E, 2019, 'Targeting AR in endocrine-resistant breast cancer', in Oncolabs, Bioscientifica, presented at 7th PacRim Breast & Prostate Cancer Meeting, http://dx.doi.org/10.1530/oncolabs.1.P012
    Conference Abstracts | 2019
    Lim E; Hickey TA; Selth LA; Chia KM; Milioli HH; Roden D; Laven-Law G; Jindal S; Hui M; Ebrahimie E; Birrell SN; Stelloo S; Caldon CE; Finlay-Schultz J; Abdel-Fatah TM; Ellis IO; Zwart W; Palmieri C; Sartorius CA; Swarbrick A; Carroll JS; Tilley WD, 2019, 'Abstract GS2-03: The androgen receptor is a tumour suppressor in estrogen receptor positive breast cancer', in Cancer Research, American Association for Cancer Research (AACR), TX, San Antonio, Vol. 80, pp. gs2-03-gs2-03, presented at 42nd Annual San Antonio Breast Cancer Symposium, TX, San Antonio, 09 December 2019 - 14 December 2019, http://dx.doi.org/10.1158/1538-7445.sabcs19-gs2-03
    Conference Abstracts | 2019
    Milioli HH; Chia KM; Portman N; Young A; Laven-Law G; Selth L; Tilley WD; Hickey T; Lim E, 2019, 'Androgen receptor activation in Endocrine-Resistant ER-positive breast cancer', in Oncolabs, Bioscientifica, presented at 7th PacRim Breast & Prostate Cancer Meeting, http://dx.doi.org/10.1530/oncolabs.1.P034
    Conference Presentations | 2019
    Portman N; Milioli HH; Alexandrou S; Coulson R; Young A; Chia KM; Haup S; Haup Y; Caldon L; Lim E, 2019, 'The MDM2 inhibitor NVP-CGM097 synergises with fulvestrant and inhibits Estrogen Receptor positive breast cancer', presented at Hormone-Dependent Cancers (GRS), Newry, USA
    Conference Abstracts | 2019
    Portman N; Milioli HH; Young A; Coulson R; Alexandrou S; Lam N; Haup S; Haup Y; Caldon L; Deng N; Lim E, 2019, 'Activation of p53 in combination with endocrine and CDK targeted therapies in ER+ breast cancer', in Oncolabs, Bioscientifica, presented at 7th PacRim Breast & Prostate Cancer Meeting, http://dx.doi.org/10.1530/oncolabs.1.P043
    Conference Abstracts | 2019
    Stirzaker C; Chia KM; Portman N; Milioli HH; Clifton S; Achinger-Kawecka J; Nair S; Lim E; Clark S, 2019, 'DNA demethylation agents as a therapeutic approach in endocrine-resistant breast cancer', in Oncolabs, presented at 7th PacRim Breast & Prostate Cancer Meeting, http://dx.doi.org/10.1530/oncolabs.1.P049
    Conference Abstracts | 2019
    Wahlroos S; Wilkinson A; Milioli H; Portman N; Gallego-Ortega D; Lim E, 2019, 'Concurrent exercise and chemotherapy in preclinical breast cancer models', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, TX, San Antonio, Vol. 80, presented at 42nd Annual San Antonio Breast Cancer Symposium, TX, San Antonio, 09 December 2019 - 14 December 2019, http://dx.doi.org/10.1158/1538-7445.SABCS19-P4-14-13
    Conference Abstracts | 2018
    Chia KM; Milioli H; Portman N; Laven-Law G; Yong A; Swarbrick A; Caldon L; Tilley W; Hickey T; Lim E, 2018, 'Abstract P6-20-04: Activation of AR inhibits growth of endocrine-resistant breast cancer', in Cancer Research, American Association for Cancer Research (AACR), TX, San Antonio, Vol. 79, pp. p6-20-04-p6-20-04, presented at San Antonio Breast Cancer Symposium, TX, San Antonio, 04 December 2018 - 08 December 2018, http://dx.doi.org/10.1158/1538-7445.sabcs18-p6-20-04
    Conference Abstracts | 2018
    Wahlroos S; Wilkinson A; Gallego-Ortega D; Febbraio M; Lim E, 2018, 'Concurrent exercise and chemotherapy in preclinical breast cancer models', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, TX, San Antonio, Vol. 79, presented at San Antonio Breast Cancer Symposium, TX, San Antonio, 04 December 2018 - 08 December 2018, http://dx.doi.org/10.1158/1538-7445.SABCS18-P6-21-05
    Conference Presentations | 2016
    Milioli HH; Riveros C; Vimieiro R; Berretta R; Moscato P, 2016, 'Pairwise biomarker combinations and predictive modelling for breast cancer intrinsic subtypes', presented at 18th EMBL PhD Symposium, Heidelberg, Germany
    Conference Abstracts | 2016
    Milioli HH; Sanhueza C; Berretta R; Moscato P, 2016, 'Breast Cancer Molecular Portraits of Intrinsic Subtypes and Integrative Clusters in the METABRIC Data Set', in Asia Pacific Journal of Clinical Oncology, Wiley, presented at Hunter Cancer Research Alliance Annual Symposium, http://dx.doi.org/10.1111/ajco.12618
    Conference Presentations | 2016
    Milioli HH; Sanhueza C; Riveros C; Berretta R; Moscato P, 2016, 'Breast cancer molecular portraits of intrinsic subtypes and integrative clusters in the METABRIC data set', presented at 2nd World Congress on Controversies in Breast Cancer (CoBrCA), Barcelona, Spain
    Conference Presentations | 2016
    Milioli HH; Tishchenko I; Riveros C; Berretta R; Moscato P, 2016, 'Basal-like breast cancers uncovered by genomic and transcriptomic profiles and patients' overall survival', presented at Sydney Cancer Conference, Sydney NSW, Australia
    Conference Abstracts | 2015
    Milioli HH; Tishchencko I; Riveros C; Berretta R; Moscato P, 2015, 'Basal-like breast cancer subgroups uncovered by genomic and transcriptomic profiles and overall survival outcomes', in Asia Pacific Journal of Clinical Oncology, Wiley, presented at Hunter Cancer Research Alliance Annual Symposium, http://dx.doi.org/10.1111/ajco.12444
    Conference Abstracts | 2015
    Milioli HH; Tishchencko I; Riveros C; Berretta R; Moscato P, 2015, 'Molecular classification of basal-like breast cancer subtypes based on predictive survival markers', in Annals of Oncology, Elsevier, presented at IMPAKT 2015 Breast Cancer Conference, http://dx.doi.org/10.1093/annonc/mdv117.11
    Conference Abstracts | 2015
    Milioli HH; Tishchencko I; Riveros C; Sakoff J; Berretta R; Moscato P, 2015, 'Consensus on breast cancer cell lines classification for an effective and efficient clinical decision-making', in Annals of Oncology, Elsevier, presented at IMPAKT 2015 Breast Cancer Conference, http://dx.doi.org/10.1093/annonc/mdv121.08
    Conference Presentations | 2015
    Milioli HH; Vimieiro R; Tishchenko I; Riveros C; Berretta R; Moscato P, 2015, 'Refining the breast cancer molecular subtypes in the METABRIC data set', presented at World Congress on Controversies in Breast Cancer (CoBRA), Melbourne VIC, Australia
    Conference Papers | 2015
    Milioli HH, 2015, 'The IMPAKT of breast cancer research: Fundamental science and applied medicine', in Future Science Oa, http://dx.doi.org/10.4155/fso.15.69
    Conference Abstracts | 2015
    Tishchencko I; Milioli HH; Riveros C; Moscato P, 2015, 'How intrinsic are luminal breast cancer subtypes?', in Asia Pacific Journal of Clinical Oncology, Wiley, presented at Hunter Cancer Research Alliance Annual Symposium, http://dx.doi.org/10.1111/ajco.12444

 

2024 - Tour de Cure (CI, AUD $50,000): Exploiting mechanisms of chemotherapy resistance: new strategies to cure cancer

2023-2025 - Cancer Council NSW (CI, AUD $370,000): Targeting cellular plasticity to prevent and treat chemotherapy-resistant disease

2020 - Cancer Clinical Academic Group E/MCR Seed Grant Scheme (AI, AUD $50,000): Targeting FGF fusions in previously untreatable cancers: A new OMICS approach for personalised cancer medicine

2019-2020 - National Breast Cancer Foundation (CI-B, AUD $200,000): Targeting the p53 pathway in the age of CDK4/6 inhibitor resistant ER positive breast cancer

2019-2021 - National Breast Cancer Foundation (AI, AUD $600,000): Therapeutic targeting of dual CDK4/6 inhibitor and endocrine resistant breast cancer

2018-2020 - Cancer Institute NSW - Early Career Fellowship (CI, AUD $600,000): Expanding the repertoire of therapies targeting sex steroid receptors in breast cancer

  • 2024 - St Vincent’s Research Week - Best Poster Award (EMCR). Sydney NSW - Australia
  • 2022 - Estee Lauder Breast Cancer Award (AUD $10 - 000). Sydney NSW - Australia
  • 2018 - Garvan Institute of Medical Research Travel Grant (AUD $1 - 000). EMCR Forum 2018. Sydney NSW - Australia
  • 2016 - EMBL Australia PhD Travel Grant (AUD $3 - 000) - 18th EMBL PhD Symposium in Heildeberg - Germany. Australia
  • 2016 - Young Scientist Award - 2nd World Congress on Controversies in Breast Cancer (CoBrCA). Barcelona - Spain
  • 2015 - Bioinfosummer 2015 Travel Bursary (AUD $500) - Australian Mathematical Sciences Institute (AMSI) - Australia
  • 2015 - BioInfoSummer 2015 - Best Poster Award. Sydney NSW - Australia
  • 2015 - Hunter Cancer Research Alliance (HCRA) PhD RESEARCH AWARD 2016 (AUD $5 - 000). Newcastle NSW - Australia
  • 2015 - Hunter Cancer Research Alliance (HCRA) Travel Grant (AUD $1 - 000). Newcastle NSW - Australia
  • 2014 - BioInfoSummer 2014 - Best Poster Presentation. Melbourne VIC - Australia
  • 2014 - International Conference on Bioinformatics (InCoB) - Best Poster Award. Sydney NSW - Australia
  • 2014 - JENNIE THOMAS MEDICAL RESEARCH Travel Grant (AUD $10 - 000) - Hunter Medical Research Institute. Newcastle NSW - Australia